1 citations
,
September 2024 in “Frontiers in Pharmacology” Aumolertinib effectively controls lung cancer and improves quality of life.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia” June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” The gene therapy showed significant wound healing and was safe for treating severe RDEB.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
December 2025 in “Frontiers in Nutrition” The albumin change rate helps predict treatment success in AIDS-related non-Hodgkin lymphoma.
1 citations
,
May 2022 in “PubMed” Both Billroth-I and Billroth-II methods have similar impacts on quality of life after gastric cancer surgery.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
October 2021 in “Research Square (Research Square)” A 532 nm laser helps tendon stem cells grow and become tendon-like by increasing Nr4a1 activity, which may speed up tendon repair.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Higher fluence in hair removal damages hair follicles more, while lower fluence mimics natural hair regression, with long-term IPL treatments effectively reducing hair.
December 2023 in “Trials” The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
18 citations
,
June 2020 in “Dermatologic Therapy” FCO2 laser is a better treatment for alopecia areata than intralesional steroids.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
74 citations
,
April 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Researchers found three patterns of Frontal fibrosing alopecia, with Pattern III having the best prognosis after treatment.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
January 2025 in “Nature Communications” Large-scale reconstructions enhance understanding of vibrissal sensory mapping in the brain.
Low-level laser therapy combined with Neoptide improved hair regrowth better than either treatment alone in rats.
April 2023 in “Journal of Investigative Dermatology” 3D ultrasound can detect hair follicle changes and disease phases in alopecia areata.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
19 citations
,
August 2018 in “Journal of the American Academy of Dermatology” Both lasers are equally effective and safe for treating freckles.
4 citations
,
July 2024 in “Radiotherapy and Oncology” A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.